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Evaluation of a daptomycin dosing protocol based on
adjusted body weight at a community hospital
Lorenzo M. Porras, Jr., Pharm.D.; Andre Moses, Pharm.D.; Hasib Sheikh, Pharm.D.

BACKGROUND/INTRODUCTION

RESULTS

• Daptomycin is a lipopeptide antibiotic indicated for the treatment of complicated
skin and skin structure infections, bacteremia resulting from Staphylococcus
aureus, and right-sided infective endocarditis.2

• A total of forty seven (47) patients were included in this study. Out of those 47
patients, 25 were treated with daptomycin prior to the revision of the protocol
and the remaining 22 were subsequent to the protocol revision.

Average Days on Daptomycin Therapy
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• There are multiple studies that support the use of adjusted body weight dosing for
daptomycin in obese patients. 2 The data from one study reported an increase of
creatinine phosphokinase (CPK) in obese patients that were dosed based on actual
body weight.1

• The average length of stay for the patients treated with daptomycin prior to the
revision of the protocol was 10.4 days, and 13.6 days post-protocol revision.
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• At South Miami Hospital (SMH), there is a daptomycin dosing protocol that was
revised. Now, pharmacists are to use adjusted body weight to dose patients with a
body mass index (BMI) above 30 kg/m2 and/or total body weight (TBW) above 20%
of their ideal body weight (IBW).

DISCUSSION

• The average CPK level for patients prior to the protocol revision was 117.95 U/L,
versus 154.32 U/L for patients after the implementation of the revised protocol.
There was an outlier in the post-protocol group with a CPK level of 1,620 U/L. This
elevated level may be attributed to factors other than daptomycin. This one
patient had an elevated temperature of 39.4 degrees Celsius in combination with
osteomyelitis.
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• This study was developed to identify the benefits of following the new daptomycin
protocol.
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• Overall, the estimated cost of therapy was lower in the post-protocol revision
group $14,469.85 (n=22), compared to $19,584.41 (n=25) prior to the protocol
revision. The estimated cost savings in the study period was $5,115.56.
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OBJECTIVES

1

Pre-protocol revision (n=25)

• The data was evaluated in order to:

Post-protocol revision (n=22)

• Limitations of this study were the small sample size, short-term study period, and
a lack of direct correlation between daptomycin therapy and length of stay.
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• Analyze the difference in patients’ length of stay at the hospital.

CONCLUSION

Estimated Cost of Daptomycin Therapy

• Calculate the cost savings subsequent to the new protocol.
• Compare CPK levels for those patients included post-protocol.
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METHODS
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• The study analyzed fifty electronic medical administration records of randomly
selected patients.

• The average duration of therapy for both study groups did not differ significantly
in this study. This supports the existing literature stating that using adjusted
body weight to dose overweight patients does not decrease the effectiveness of
daptomycin.
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• This is a retrospective study that was approved by the Baptist Health South
Florida Institutional Review Board.
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• An electronic report was generated, including patients that were treated with
daptomycin from 02/01/2018 – 10/01/2018. All patients were eighteen years of
age or older and had a total body weight of greater than twenty percent of their
ideal body weight.
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Pre-protocol revision (n=25)

Post-protocol revision (n=22)
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• The protocol that is utilized at SMH proposes benefit not only for the patient but
also for the institution. These benefits include decreasing unnecessary exposure
to higher doses of daptomycin for patients and cost savings for the institution.
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• Twenty-five patient reports were compared prior to the protocol implementation
date versus twenty-five patient charts after the implementation date of
06/12/2018.
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• Duration of therapy for daptomycin was similar among the two studied groups.
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and patients after the protocol revision were treated for 3.77 days on average.
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DISCLOSURES
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N=25
Females
Males

14 (56%)
11 (44%)

N=22
8 (36%)
14 (64%)

BMI
(kg/m2)

30.5

TBW/IBW
(%)

40.6

Length of
stay (days)

10.4
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